Match!

Genomic Markers in Prostate Cancer Decision Making

Published on Nov 1, 2017in European Urology17.30
· DOI :10.1016/j.eururo.2017.10.036
Vito Cucchiara4
Estimated H-index: 4
(UC Davis: University of California, Davis),
Matthew R. Cooperberg55
Estimated H-index: 55
(UCSF: University of California, San Francisco)
+ 4 AuthorsChristopher H Evans108
Estimated H-index: 108
(UC Davis: University of California, Davis)
View in Source
Abstract
Abstract Context Although the widespread use of prostate-specific antigen (PSA) has led to an early detection of prostate cancer (PCa) and a reduction of metastatic disease at diagnosis, PSA remains one of the most controversial biomarkers due to its limited specificity. As part of emerging efforts to improve both detection and management decision making, a number of new genomic tools have recently been developed. Objective This review summarizes the ability of genomic biomarkers to recognize men at high risk of developing PCa, discriminate clinically insignificant and aggressive tumors, and facilitate the selection of therapies in patients with advanced disease. Evidence acquisition A PubMed-based literature search was conducted up to May 2017. We selected the most recent and relevant original articles and clinical trials that have provided indispensable information to guide treatment decisions. Evidence synthesis Genome-wide association studies have identified several genetic polymorphisms and inherited variants associated with PCa susceptibility. Moreover, the urine-based assays SelectMDx, Mi-Prostate Score, and ExoDx have provided new insights into the identification of patients who may benefit from prostate biopsy. In men with previous negative pathological findings, Prostate Cancer Antigen 3 and ConfirmMDx predicted the outcome of subsequent biopsy. Commercially available tools (Decipher, Oncotype DX, and Prolaris) improved PCa risk stratification, identifying men at the highest risk of adverse outcome. Furthermore, other biomarkers could assist in treatment selection in castration-resistant PCa. AR-V7 expression predicts resistance to abiraterone/enzalutamide, while poly(ADP-ribose) polymerase-1 inhibitor and platinum-based chemotherapy could be indicated in metastatic patients who are carriers of mutations in DNA mismatch repair genes. Conclusions Introduction of genomic biomarkers has dramatically improved the detection, prognosis, and risk evaluation of PCa. Despite the progress made in discovering suitable biomarker candidates, few have been used in a clinical setting. Large-scale and multi-institutional studies are required to validate the efficacy and cost utility of these new technologies. Patient summary Prostate cancer is a heterogeneous disease with a wide variability. Genomic biomarkers in combination with clinical and pathological variables are useful tools to reduce the number of unnecessary biopsies, stratify low-risk from high-risk tumors, and guide personalized treatment decisions.
  • References (64)
  • Citations (24)
References64
Newest
#1Siebren Dijkstra (Radboud University Nijmegen)H-Index: 7
#2Tim M. Govers (Radboud University Nijmegen)H-Index: 4
Last.Inge M. van Oort (Radboud University Nijmegen)H-Index: 22
view all 9 authors...
10 CitationsSource
#1Gregg EureH-Index: 7
#2Robert GivenH-Index: 14
Last.Bela DenesH-Index: 9
view all 11 authors...
10 CitationsSource
#1Samir S. Taneja (NYU: New York University)H-Index: 50
27 CitationsSource
#1John L. Gore (Seattle Cancer Care Alliance)H-Index: 5
Last.Daniel W. Lin (Seattle Cancer Care Alliance)H-Index: 50
view all 25 authors...
10 CitationsSource
#2Changxue LuH-Index: 15
Last.Jun LuoH-Index: 42
view all 15 authors...
134 CitationsSource
#1Deepansh Dalela (HFHS: Henry Ford Health System)H-Index: 15
Last.AbdollahFiras (HFHS: Henry Ford Health System)H-Index: 44
view all 13 authors...
21 CitationsSource
#1Jennifer M. Lobo (UVA: University of Virginia)H-Index: 6
#2Daniel M. Trifiletti (UVA: University of Virginia)H-Index: 11
Last.Timothy N. Showalter (UVA: University of Virginia)H-Index: 22
view all 11 authors...
7 CitationsSource
#1Jonathan S. Brajtbord (UCSF: University of California, San Francisco)H-Index: 9
#2Michael Leapman (UCSF: University of California, San Francisco)H-Index: 12
Last.Matthew R. Cooperberg (UCSF: University of California, San Francisco)H-Index: 55
view all 3 authors...
21 CitationsSource
#1Joaquin Mateo (ICR: Institute of Cancer Research)H-Index: 22
#2Gunther Boysen (ICR: Institute of Cancer Research)H-Index: 14
Last.Johann S. de Bono (ICR: Institute of Cancer Research)H-Index: 97
view all 10 authors...
58 CitationsSource
#1Daniel E. Spratt (UM: University of Michigan)H-Index: 29
#2Kasra YousefiH-Index: 16
Last.Felix Y. Feng (UCSF: University of California, San Francisco)H-Index: 54
view all 23 authors...
48 CitationsSource
Cited By24
Newest
#1Zheng-Ju Ren (Sichuan University)H-Index: 3
#2Dehong Cao (Sichuan University)H-Index: 5
Last.Qiang Dong (Sichuan University)H-Index: 11
view all 8 authors...
Source
#1Xin Chen (HUST: Huazhong University of Science and Technology)H-Index: 4
#2Na Liu (HUST: Huazhong University of Science and Technology)H-Index: 2
Last.Xianjin Xiao (HUST: Huazhong University of Science and Technology)H-Index: 3
view all 11 authors...
Source
#1İsmail Selvi (Karabük University)H-Index: 1
#2Halil Basar (Health Science University)
Last.Ozlem Kaymaz (Ankara University)
view all 5 authors...
Source
#1Marc A. BjurlinH-Index: 20
#2Audrey Renson (CUNY: City University of New York)H-Index: 5
Last.Samir S. TanejaH-Index: 50
view all 7 authors...
5 CitationsSource
#1Junfeng Xu (University of Texas MD Anderson Cancer Center)H-Index: 1
#2Wen-Shin Chang (PRC: China Medical University (PRC))H-Index: 1
Last.Jian Gu (University of Texas MD Anderson Cancer Center)H-Index: 49
view all 8 authors...
Source
Source
#1Risa B. Burns (BIDMC: Beth Israel Deaconess Medical Center)H-Index: 16
#2Aria F. Olumi (BIDMC: Beth Israel Deaconess Medical Center)H-Index: 30
Last.Gerald W. Smetana (BIDMC: Beth Israel Deaconess Medical Center)H-Index: 23
view all 4 authors...
Source
#1Simon P. Kim (Yale University)H-Index: 31
#2Jon C. Tilburt (Mayo Clinic)H-Index: 25
Last.Cary P. Gross (Yale University)H-Index: 52
view all 9 authors...
Source
#1Umberto AnceschiH-Index: 4
#2Gabriele TudertiH-Index: 4
Last.Giuseppe SimoneH-Index: 20
view all 13 authors...
4 CitationsSource
#1Mina M. Fam (University of Pittsburgh)H-Index: 1
#2Jonathan Yabes (University of Pittsburgh)H-Index: 14
Last.Bruce L. Jacobs (University of Pittsburgh)H-Index: 18
view all 10 authors...
Source